US2425285A - Activated iodine therapeutic agent - Google Patents
Activated iodine therapeutic agent Download PDFInfo
- Publication number
- US2425285A US2425285A US572423A US57242345A US2425285A US 2425285 A US2425285 A US 2425285A US 572423 A US572423 A US 572423A US 57242345 A US57242345 A US 57242345A US 2425285 A US2425285 A US 2425285A
- Authority
- US
- United States
- Prior art keywords
- iodine
- therapeutic agent
- activated
- oxygen
- scalp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title description 12
- 229940124597 therapeutic agent Drugs 0.000 title description 12
- 150000002496 iodine Chemical class 0.000 title description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical class [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 15
- 239000011630 iodine Substances 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 210000004761 scalp Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 7
- 229930002875 chlorophyll Natural products 0.000 description 6
- 235000019804 chlorophyll Nutrition 0.000 description 6
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 6
- 239000003504 photosensitizing agent Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 241000893966 Trichophyton verrucosum Species 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- -1 compound heme Chemical class 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 229960004995 magnesium peroxide Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 101150104377 Ecel1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
Definitions
- This invention relates to therapeutic agents and more particularly to a therapeutic agent containing iodine.
- The'invention further relates to therapeutic agents adapted for the treatment of fungus infections of the scalp and of the skin,
- tonsurans, ringworm of the groin and ringworm of the feet or athletes foot are particularly to time.
- iodine has, for the ringworm fungi, fungistatic and fungicidal properties, but no wholly satisfactory provisions have heretofore been made for utilizing theiodine in an eflective'manner withoutirritation or injury of the skin and body tissues upon application.
- the fungicidal properties of iodine are utilized but with an enhanced or intensified action not heretofore obtained and without irritation of the skin and body tissues.
- the iodine is combined with a catalyst, in a suitable environment, and in a suitable vehicle for local application.
- chlorophyll is employed as a catalyst and photosensitizer as it possesses the required characteristics of accelerating the chemical reaction, While itself remaining unaltered, and becaues of its function as a photosensitizer in promoting oxidation by oxygen present in the therapeutic agent.
- the photodynamic action desired requires a source of oxygen, and also that iron be present. While any suitable sources of oxygen and iron may be employed, capable of providing the oxygen required for the occurrence of the photodynamic process, it has been found that red blood cells, of human or animal blood, are satisfactory because of their oxygen carrying capacities and also because the iron containing compound heme, which goes to make up the hemoglobin of the red blood cells, supplies the iron which is also 2 essential to the progress of the photodynamic process. Y
- Photodynamic processes also require a source of,energy and for this purpose a quartz-mercury arc; with most of its energy in the 2600 to 2900 A level, is employed as hereinafter pointed out.
- the therapeutic agent in accordance with the present invention is preferably prepared by combining the ingredients in the manner hereinafter pointed out, it beingunderstood that the proportions may be varied and substitutions made without departing from the spirit of the invention.
- a measured quantity of iodine crystals and a measured quantity of a source of oxygen, such as magnesium peroxide are mixed in one vessel in dry form.
- measured quantities of red blood cells in normal salt solution, a. catalytic agent in liquid form such as chlorophyll, and a wetting agent, such as dioctyl ester of sodium sulfosuccinic acid which is distributed under the trade name Deceresol are mixed and combined.
- the quantities employed are preferably as follows:
- the materials in the two vessels are brought together and intimately mixed and the mixture is kept, under an ultra-violet light, such as from the energy source referred to above, until dry, this drying ordinarily requires from three to five days.
- This iodine containing residue thus obtained is reddish-black and contains about 15% by weight of iodine and about 0.8% by weight of inorganic material.
- the iodine containing material is then ground up and is incorporated in a suitable vehicle or dispersing material, cottonseed oil having been found satisfactory for this purpose.
- the iodine containing material and' cottonseed oil are preferably in the proportions of one half drachm to one ounce, respectively.
- the iodine molecule is capable, in the presence of the photosensitizing agent, of having energy of activation transferred thereto from the photosensitizer molecules of chlorophyll.
- the iodine molecule in the presence of the chlor'o phyll and with iron and oxygen present becomes an activated molecule and thereby capable of more intensive action and efiect.
- the acetic acid is rubbed into the scalp using a small brush, such as a tooth brush, ior' about two minutes, with special attention to the infected areas.
- Acetic acid of such strength redu'ces the activity orthe ringworm fungus and has proven eific'i eiit and nan-irri ating.
- the at: plication of the acetic acid is' folhwed by brin me an electric light bulb of: 150to 200 watt size sufficiently close to the scalp to impart a distinct sensation 5f heat.
- p N W p U The io hamm r-m1 is then rubbed into the s ell?
- a therapeutic agent for topical application comprising io'dine activated by ultra-violet light in the presence of chlorophyll, heme as a source of iron, and a material continuously evolving oxygen.
- a therapeutic agent for topical application comprisingiodine activated by ultra-violet light the presene of chlorophyll, hemoglobin, and a material continuously evolving oxygen.
- a therapeutic agent for topical application cfifipris'iiig iodine activated by ultra-violet light in the presence of chlorophyll, red blood cells, and magnesium peroxide.
- a therapeutic agent, for topical application comprising iodine activated by ultra-violet light in the presence of chlorophylLheine as 'a. 's'fi'u'i'ce of iron, and a "material continuously volvihl'; oxygen, the activated iodine Being aistnulevard in an oily vehicle.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
v) Patented Aug. 5, 1947 ACTIVATED IODINE THERAPEUTIC AGENT Albert Strickler, Philadelphia, Pa, assignor to The Hersch-Razel Research Foundation, Phila-' delphia, Pa., a corporation of Pennsylvania No Drawing. 7 Application January 11, 1945,
Serial No. 572,423
4 Claims. (01. 167-58) This invention relates to therapeutic agents and more particularly to a therapeutic agent containing iodine. The'invention further relates to therapeutic agents adapted for the treatment of fungus infections of the scalp and of the skin,
7 and particularly to time. tonsurans, ringworm of the groin and ringworm of the feet or athletes foot.
Various treatments have heretofore been proposed for fungus infections of the skin and of the scalp but none of these have proven satisfactory. Difficulties have arisen particularly because in certain types of treatment the hair cells are de-. stroyed, resulting in permanentbaldness of the scalp areas subjected to treatment, or in other instances the results obtained have not justified continuance of the treatment. In other instances the irritating nature of the treatment or of the agents employed has resulted in severe discomforts and dissatisfaction.
It has heretofore been recognized that iodine has, for the ringworm fungi, fungistatic and fungicidal properties, but no wholly satisfactory provisions have heretofore been made for utilizing theiodine in an eflective'manner withoutirritation or injury of the skin and body tissues upon application.
In accordance with the present invention, the fungicidal properties of iodine are utilized but with an enhanced or intensified action not heretofore obtained and without irritation of the skin and body tissues.
In order to utilize the properties of the iodine in a more effective manner the iodine is combined with a catalyst, in a suitable environment, and in a suitable vehicle for local application.
In order to intensify and augment the action of the iodine as a fungicidal agent chlorophyll is employed as a catalyst and photosensitizer as it possesses the required characteristics of accelerating the chemical reaction, While itself remaining unaltered, and becaues of its function as a photosensitizer in promoting oxidation by oxygen present in the therapeutic agent.
The photodynamic action desired requires a source of oxygen, and also that iron be present. While any suitable sources of oxygen and iron may be employed, capable of providing the oxygen required for the occurrence of the photodynamic process, it has been found that red blood cells, of human or animal blood, are satisfactory because of their oxygen carrying capacities and also because the iron containing compound heme, which goes to make up the hemoglobin of the red blood cells, supplies the iron which is also 2 essential to the progress of the photodynamic process. Y
An additional source of oxygen is preferably employed and for this purpose magnesium peroxide has been found satisfactory.
' .Photodynamic processes also require a source of,energy and for this purpose a quartz-mercury arc; with most of its energy in the 2600 to 2900 A level, is employed as hereinafter pointed out.
The therapeutic agent in accordance with the present invention is preferably prepared by combining the ingredients in the manner hereinafter pointed out, it beingunderstood that the proportions may be varied and substitutions made without departing from the spirit of the invention. a a
As an illustration of a specific example of the preparation of a therapeutic agent in accordance with the present invention, a measured quantity of iodine crystals and a measured quantity of a source of oxygen, such as magnesium peroxide, are mixed in one vessel in dry form. In another vessel. measured quantities of red blood cells in normal salt solution, a. catalytic agent in liquid form such as chlorophyll, and a wetting agent, such as dioctyl ester of sodium sulfosuccinic acid which is distributed under the trade name Deceresol, are mixed and combined. The quantities employed are preferably as follows:
Wetting agent, dioctyl ester of sodium sulfosuccinic acid 1.0
The materials in the two vessels are brought together and intimately mixed and the mixture is kept, under an ultra-violet light, such as from the energy source referred to above, until dry, this drying ordinarily requires from three to five days. This iodine containing residue thus obtained is reddish-black and contains about 15% by weight of iodine and about 0.8% by weight of inorganic material. The iodine containing material is then ground up and is incorporated in a suitable vehicle or dispersing material, cottonseed oil having been found satisfactory for this purpose. The iodine containing material and' cottonseed oil are preferably in the proportions of one half drachm to one ounce, respectively.
While it is not entirely certain as to the action which takes place, it appears likely that the iodine molecule is capable, in the presence of the photosensitizing agent, of having energy of activation transferred thereto from the photosensitizer molecules of chlorophyll. In this manner the iodine molecule in the presence of the chlor'o phyll and with iron and oxygen present becomes an activated molecule and thereby capable of more intensive action and efiect. There may also :be a promotion of oxidation by the l'iloi'iF phyll in its role as a photosensitizer as well ,as some generation of ozone by the ultra violt light. M q 7 In the treatment of tinea tonsurans the hair of the scalp is clipped and is kept sliort-. sue"- cessive topical applications are employed etasisting of acetic acid, 3% solution, and the iodine combination.
First, the acetic acid is rubbed into the scalp using a small brush, such as a tooth brush, ior' about two minutes, with special attention to the infected areas. Acetic acid of such strength redu'ces the activity orthe ringworm fungus and has proven eific'i eiit and nan-irri ating. The at: plication of the acetic acidis' folhwed by brin me an electric light bulb of: 150to 200 watt size sufficiently close to the scalp to impart a distinct sensation 5f heat. p N W p U The io hamm r-m1 is then rubbed into the s ell? ,by an tr with a small brush, such as a toothbrush, for aboiit two minutes, followed y applijcation of the electric bulb as before, ioi abouts'ix minutes, The use of 'the electr c pint possibly induces some vaporir'atioii of the iodine. A The therapeutic, agents employed have been found effective in trea meat'orrm wo'rm of the tor madam; type, and also 12 QJ'P'Seiiin variety.
UK U ed for deterin'ha tion of a cure consisted of d rect examinations prthe suspected hair aha observation or t scalp hair with filtejre d, i'zltra violetlig'ht Three consecutive ne ative observations by both methods made at four to) fiveday intervals, were considered essential the persons treated icdi lld he regarded as cure The iodine containing material is also suitable for use in the treatment of fungi infections, other than those of the scalp, which do not require as detailed preliminary preparations.
I claim:
1. A therapeutic agent for topical application comprising io'dine activated by ultra-violet light in the presence of chlorophyll, heme as a source of iron, and a material continuously evolving oxygen.
"2. A therapeutic agent for topical application comprisingiodine activated by ultra-violet light the presene of chlorophyll, hemoglobin, and a material continuously evolving oxygen.
3. A therapeutic agent for topical application cfifipris'iiig iodine activated by ultra-violet light in the presence of chlorophyll, red blood cells, and magnesium peroxide.
4. A therapeutic agent, for topical application comprising iodine activated by ultra-violet light in the presence of chlorophylLheine as 'a. 's'fi'u'i'ce of iron, and a "material continuously volvihl'; oxygen, the activated iodine Being aistntatea in an oily vehicle. r
. ALBERT STRIGKIER.
Ci'iiiri The following references are of record in the file of this patent:
Merck Manual, "zen ed. (1956) pa e 772.
-'ormscyni seages or the Skin (1934'), 4th ad, age 995. na l-58R) Elli's af1d we la-cnmi cai A tion 61 Ultravitjlt ays '(194l), paes 231, 264, 27?, 451,498, 522, 678, 860 aria 862.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US572423A US2425285A (en) | 1945-01-11 | 1945-01-11 | Activated iodine therapeutic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US572423A US2425285A (en) | 1945-01-11 | 1945-01-11 | Activated iodine therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2425285A true US2425285A (en) | 1947-08-05 |
Family
ID=24287745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US572423A Expired - Lifetime US2425285A (en) | 1945-01-11 | 1945-01-11 | Activated iodine therapeutic agent |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2425285A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2742909A (en) * | 1951-08-14 | 1956-04-24 | Turner Hall Corp | Respiratory pigments of blood in setting permanent waves |
| US4147775A (en) * | 1976-10-06 | 1979-04-03 | Schwartz Stephen H | Antiseptic composition |
| US4937072A (en) * | 1986-05-12 | 1990-06-26 | Kessler Jack H | In situ sporicidal disinfectant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB414098A (en) * | 1900-01-01 | |||
| US2120667A (en) * | 1937-12-01 | 1938-06-14 | Lakeland Foundation | Therapeutic agent for use in the treatment of infection |
-
1945
- 1945-01-11 US US572423A patent/US2425285A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB414098A (en) * | 1900-01-01 | |||
| US2120667A (en) * | 1937-12-01 | 1938-06-14 | Lakeland Foundation | Therapeutic agent for use in the treatment of infection |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2742909A (en) * | 1951-08-14 | 1956-04-24 | Turner Hall Corp | Respiratory pigments of blood in setting permanent waves |
| US4147775A (en) * | 1976-10-06 | 1979-04-03 | Schwartz Stephen H | Antiseptic composition |
| US4937072A (en) * | 1986-05-12 | 1990-06-26 | Kessler Jack H | In situ sporicidal disinfectant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Travagli et al. | Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims | |
| Saniabadi et al. | Vessel wall injury and arterial thrombosis induced by a photochemical reaction | |
| US3954974A (en) | Disinfectant for the surface of human body parts containing hydrogen peroxide | |
| JPH06206825A (en) | Agent for treatment of dermatosis caused by trichophyton, eczema, etc., and agent for skin disinfection and activation | |
| Kobayashi et al. | Bactericidal effect of hydroxyl radicals generated from a low concentration hydrogen peroxide with ultrasound in endodontic treatment | |
| ES2176190T3 (en) | INHIBITORS OF THE ACTIVITY OF SEX STEROIDS. | |
| ES417377A1 (en) | Salt of S-adenosil-L-methionine and process of preparation | |
| SHAPIRO et al. | Undecylenic acid in the treatment of dermatomycosis | |
| CN1635879A (en) | Application of Targeted Oxidative Therapeutic Agents in Arteriosclerosis | |
| US2425285A (en) | Activated iodine therapeutic agent | |
| CZ283011B6 (en) | Pharmaceutical composition for treating vulvitis or vulvovaginitis symptoms | |
| Lewis et al. | Ringworm of the Scalp: Clinical Data on Recent Cases; Experiences with Local Endocrine Therapy | |
| Gulafsha et al. | Miracle of ozone in dentistry: An overview | |
| CN100391449C (en) | Use of chloramine-T for the treatment of diseases of the skin, mucous membranes, organs and tissues | |
| JPS58198421A (en) | Composition for decoloring skin and treating skin disease | |
| RU2008898C1 (en) | Method for treatment of fungus disease or virus disease of skin and/or nail plate | |
| Mkhoyan et al. | The use of an Ozone Generator that Produces Ozone Using Ultraviolet Radiation for Ozonize the Contact Medium in the Treatment of Gingivitis of Young People | |
| Strickler | Tinea capitis: Its treatment with special iodine and dilute acetic acid | |
| Koulu et al. | Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath—psoralens plus ultraviolet A treatment: Comparison of 8-methoxypsoralen and trimethylpsoralen photos ensitization | |
| Abdulkareem et al. | The efficacy of ozonated saline solution against protoscoleces of cystic echinococcosis in liver hydatid surgery | |
| Tapia et al. | Ozone therapy and its scientific foundations | |
| JP3516952B2 (en) | Topical composition for medical use | |
| Sallinen | Early history of ozone therapies | |
| McGAVACK et al. | Influence of Tetra-Chloro-Para-Benzoquinone on Human Fungous Infections | |
| Smeenk et al. | Allergic contact eczema due to chloracetamide |